PMID- 24740745
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20140417
IS  - 1201-5989 (Print)
IS  - 1201-5989 (Linking)
VI  - 19
IP  - 2
DP  - 2014 Mar-Apr
TI  - Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities 
      associated with novel therapies.
PG  - 1-4
AB  - The last couple of years have seen the beginning of a new era in the treatment of 
      metastatic melanoma. This disease is typically characterized by its poor 
      prognosis and limited choice of therapy. Two mechanistically diverse classes of 
      agents - BRAF inhibitors and immune modulators - have demonstrated an overall 
      survival benefit. Along with their significant clinical benefits, there are also 
      unique adverse events (AEs) related to these agents. While most of the AEs are 
      mild and easily managed with supportive treatment, others require more aggressive 
      management strategies. Education of all members of the multidisciplinary care 
      team and awareness of these toxicities are crucial in order to optimize patient 
      outcomes. The landscape of melanoma is continually evolving as ongoing trials are 
      evaluating monotherapy and combination options. While these regimens continue to 
      show promise for the future, understanding and managing toxicities of currently 
      available therapies is required.
FAU - Claveau, Joel
AU  - Claveau J
AD  - Centre Hospitalier Universitaire de Quebec, Hotel-Dieu de Quebec; Melanoma and 
      Skin Cancer Clinic, Quebec City, QC, Canada; Department of Dermatologic Oncology, 
      British Columbia Cancer Agency, and Department of Dermatology and Science, 
      University of British Columbia, Vancouver, BC, Canada; Division of Medical 
      Oncology/Hematology, Odette Cancer Centre, Toronto, ON, Canada.
FAU - Ho, Vincent
AU  - Ho V
FAU - Petrella, Teresa
AU  - Petrella T
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Skin Therapy Lett
JT  - Skin therapy letter
JID - 9891441
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Humans
MH  - Melanoma/*drug therapy/pathology
MH  - Neoplasm Metastasis
MH  - Patient Care Team/organization & administration
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors
MH  - Skin Diseases/chemically induced/*prevention & control
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Survival Rate
EDAT- 2014/04/18 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/04/18 06:00
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
AID - antineoplastic agents, BRAF inhibitors, CTLA-4 antigen, immunomodulatory agents, 
      lymphatic metastasis, melanoma, skin neoplasms [pii]
PST - ppublish
SO  - Skin Therapy Lett. 2014 Mar-Apr;19(2):1-4.